Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Inclusion criteria

• histologically or cytologically documented relapsed and/or refractory hematologic malignancy
• Karnofsky Performance Status (KPS) of >70%.
• Must be ≥18 years of age.
• Expected survival >1 month.
• Women of child-bearing potential must use accepted contraceptive methods
• No radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy within the 3 weeks prior to treatment with CPI-613.

Exclusion criteria

• Serious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity.
• Patients with active central nervous system (CNS) or epidural tumor.
• Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease).
• Pregnant women, or women of child-bearing potential not using reliable means of contraception.
• Lactating females because the potential of excretion of CPI-613 into breast milk.
• Life expectancy less than 1 month.
• Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.